KR20170044172A - 티에노트리아졸로디아제핀 화합물을 함유하는 약학적 조성물을 사용하여 급성 골수성 백혈병 또는 급성 림프구성 백혈병을 치료하는 방법 - Google Patents

티에노트리아졸로디아제핀 화합물을 함유하는 약학적 조성물을 사용하여 급성 골수성 백혈병 또는 급성 림프구성 백혈병을 치료하는 방법 Download PDF

Info

Publication number
KR20170044172A
KR20170044172A KR1020177007647A KR20177007647A KR20170044172A KR 20170044172 A KR20170044172 A KR 20170044172A KR 1020177007647 A KR1020177007647 A KR 1020177007647A KR 20177007647 A KR20177007647 A KR 20177007647A KR 20170044172 A KR20170044172 A KR 20170044172A
Authority
KR
South Korea
Prior art keywords
compound
solid dispersion
formula
pharmaceutically acceptable
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020177007647A
Other languages
English (en)
Korean (ko)
Inventor
에르베 돔브레
Original Assignee
온코에틱스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 온코에틱스 게엠베하 filed Critical 온코에틱스 게엠베하
Publication of KR20170044172A publication Critical patent/KR20170044172A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y10S514/908—

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020177007647A 2014-08-28 2015-08-28 티에노트리아졸로디아제핀 화합물을 함유하는 약학적 조성물을 사용하여 급성 골수성 백혈병 또는 급성 림프구성 백혈병을 치료하는 방법 Withdrawn KR20170044172A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462043063P 2014-08-28 2014-08-28
US62/043,063 2014-08-28
PCT/EP2015/069754 WO2016030509A1 (en) 2014-08-28 2015-08-28 Methods of treating acute myeloid leukemia or acute lymphoid leukemia using pharmaceutical compositions containing thienotriazolodiazepine compounds

Publications (1)

Publication Number Publication Date
KR20170044172A true KR20170044172A (ko) 2017-04-24

Family

ID=54012215

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177007647A Withdrawn KR20170044172A (ko) 2014-08-28 2015-08-28 티에노트리아졸로디아제핀 화합물을 함유하는 약학적 조성물을 사용하여 급성 골수성 백혈병 또는 급성 림프구성 백혈병을 치료하는 방법

Country Status (6)

Country Link
US (1) US20170281642A1 (enExample)
EP (1) EP3185871A1 (enExample)
JP (1) JP2017529332A (enExample)
KR (1) KR20170044172A (enExample)
CN (1) CN107427524A (enExample)
WO (1) WO2016030509A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210106156A (ko) * 2020-02-20 2021-08-30 한국과학기술원 Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조퓨란-피라졸 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160145833A (ko) * 2014-05-02 2016-12-20 온코에틱스 게엠베하 티에노트리아졸로디아제핀 화합물을 사용한 급성 골수성 백혈병 및/또는 급성 림프아구성 백혈병의 치료 방법
EP3365335B1 (en) 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
US10159660B2 (en) * 2016-07-29 2018-12-25 Oncternal Therapeutics, Inc. Uses of indolinone compounds
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
CN113474337A (zh) 2018-12-19 2021-10-01 奥瑞生物药品公司 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物
US20220251105A1 (en) * 2019-05-17 2022-08-11 Celgene Car Llc Methods of treating a mk2-mediated disorder
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
US20230115945A1 (en) 2019-12-30 2023-04-13 Tyra Biosciences, Inc. Aminopyrimidine compounds
BR112022018553A2 (pt) * 2020-03-18 2022-11-29 Metacrine Inc Formulações de um agonista do receptor x farnesoide
CR20230325A (es) 2020-12-30 2023-12-11 Tyra Biosciences Inc Compuestos de indazol como inhibidores de cinasas
US20240190849A1 (en) 2021-02-26 2024-06-13 Tyra Biosciences, Inc. Aminopyrimidine compounds and methods of their use
CA3260633A1 (en) 2022-06-29 2024-01-04 Tyra Biosciences, Inc. POLYMORPHIC COMPOUNDS AND THEIR USES
CA3259217A1 (en) 2022-06-29 2024-01-04 Tyra Biosciences, Inc. Indazole compounds
WO2024138112A1 (en) 2022-12-22 2024-06-27 Tyra Biosciences, Inc. Indazole compounds
WO2025129014A1 (en) 2023-12-15 2025-06-19 Tyra Biosciences, Inc. Indazole compounds for the treatment of cancer
WO2025222097A1 (en) 2024-04-19 2025-10-23 Tyra Biosciences, Inc. Indazole-based protac degraders and their anticancer activity
WO2026035809A1 (en) 2024-08-06 2026-02-12 Tyra Biosciences, Inc. Indazole compounds for the treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2412776C (en) * 2000-06-16 2011-03-15 Mitsubishi Pharma Corporation Compositions controlling release ph range and/or speed
US8476260B2 (en) * 2007-12-28 2013-07-02 Mitsubishi Tanabe Pharma Corporation Antitumor agent
MX373121B (es) * 2010-05-14 2020-04-30 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
MX384074B (es) * 2010-05-14 2025-03-12 Dana Farber Cancer Inst Inc Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos.
DE102011082013A1 (de) * 2011-09-01 2013-03-07 Bayer Pharma AG 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
MX2015003771A (es) * 2012-09-28 2016-03-04 Oncoethix Gmbh Formulacion farmaceutica que contiene compuestos de tienotriazolodiazepina.
CN106029077A (zh) * 2013-08-01 2016-10-12 翁科埃斯克斯有限公司 包含噻吩并三唑并二氮杂卓化合物的药物制剂
CN105960239A (zh) * 2013-11-27 2016-09-21 翁科埃斯克斯有限公司 利用含有噻吩并三唑并二氮杂*化合物的药物制剂治疗白血病的方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210106156A (ko) * 2020-02-20 2021-08-30 한국과학기술원 Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조퓨란-피라졸 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
US20170281642A1 (en) 2017-10-05
CN107427524A (zh) 2017-12-01
JP2017529332A (ja) 2017-10-05
WO2016030509A1 (en) 2016-03-03
EP3185871A1 (en) 2017-07-05

Similar Documents

Publication Publication Date Title
US20170281642A1 (en) Methods of treating acute myeloid leukemia or acute lymphoid leukemia using pharmaceutical compositions containing thienotriazolodiazepine compounds
AU2013340483B2 (en) Pharmaceutical formulation containing thienotriazolodiazepine compounds
KR20170002550A (ko) 티에노트리아졸로디아제핀 화합물을 사용한 내성 비호지킨 림프종, 수아세포종, 및/또는 alk+ 비소세포 폐암의 치료 방법
KR20160145833A (ko) 티에노트리아졸로디아제핀 화합물을 사용한 급성 골수성 백혈병 및/또는 급성 림프아구성 백혈병의 치료 방법
WO2015018522A1 (en) Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
KR20160037201A (ko) Bet-브로모도메인 억제제를 사용한 미만성 거대 b-세포 림프종 (dlbcl)의 치료 방법
KR20160079823A (ko) 티에노트리아졸로디아제핀 화합물을 함유하는 제약 제제를 사용하여 백혈병을 치료하는 방법
KR20170002610A (ko) 티에노트리아졸로디아제핀 화합물을 사용한 삼중 음성 유방암의 치료 방법
WO2015169953A1 (en) Method of treating glioma using thienotriazolodiazepine compounds
US9795612B2 (en) Pharmaceutical formulation containing thienotriazolodiazepine compounds
KR20170037670A (ko) 티에노트리아졸로디아제핀 화합물을 사용한 림프종의 치료 방법
WO2015168587A1 (en) Method of treating resistant multiple myeloma and mantle cell lymphoma using thienotriazolodiazepine compounds

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170320

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination